摘要
Osteogenesis imperfecta(OI)is a genetic bone disease characterized by increased bone fragility and recurrent bone fractures. It belongs to orphan diseases of which the diagnosis and treatment are facing challenges. The effective treatments targeting at the underlying causes are still unavailable. Recently, many agents have been demonstrated to increase bone mineral density, improve bone microstructures, and reduce the incidence of fractures. Herein, we review the progress in new drugs for the treatment of OI.
| 源语言 | 英语 |
|---|---|
| 页（从-至） | 173-177 |
| 页数 | 5 |
| 期刊 | Journal of International Pharmaceutical Research |
| 卷 | 44 |
| 期 | 2 |
| DOI | |
| 出版状态 | 已出版 - 28 2月 2017 |
| 已对外发布 | 是 |